AZD3470 for Blood Cancers (Lymphoma)
This study is testing a new drug called AZD3470, either by itself or with other cancer medicines like Pembrolizumab, for people with certain blood cancers (hematologic malignancies) including different types of lymphoma. The main goals are to see how safe AZD3470 is, what side effects it causes, and how well your body handles it. Researchers will also look at early signs of how effective it might be. You could be eligible if you have good overall health and organ function. Some parts of the study are for adults aged 18 and older, while others may include adolescents aged 12 and older who weigh at least 40 kg. The study aims to find the best dose of AZD3470.
- Study design
- This is an open-label, multi-center study, meaning you and your doctors will know which treatment you are receiving. It plans to enroll 161 participants and is designed in different modules to test AZD3470 alone or with other drugs.
- What's involved
- You will receive AZD3470 orally. Your safety will be monitored continuously from screening until 28 days after your last dose of study medication.
- Compensation
- Not stated in the trial record.
- Follow-up
- Your safety will be monitored for at least 28 days after your last dose of study medication.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.
At a glance
Conditions
Where it's being run
37 sites across 16 statesWho to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Incidence and severity of adverse events (AEs) and serious adverse events (SAEs)From Screening continuously until 28 days after the last dose of study medication.
AEs: Number of patients with adverse events by system organ class and preferred term. SAEs: Number of patients with serious adverse events by system organ class and preferred term.
- Incidence of DLTs (Dose Escalation Cohorts only)From first dose of AZD3470 to end of Cycle 1 (each cycle is 21 days).
In the Dose Escalation cohorts in Part A, the number of participants with at least 1 dose-limiting toxicity (DLT), which is any toxicity defined as a DLT in the Clinical Study Protocol.